Gene Therapy

  • Image attribution tooltip
    Seth Babin/BioPharma Dive
    Deep Dive

    Heart attacks struck Sek Kathiresan's family. He's devoted his life to stopping them.

    After several family members had early heart attacks, Kathiresan vowed to understand why they happen. His research journey has changed medical practice and led to a new biotech startup, Verve Therapeutics, that seeks to prevent them.

    By Nov. 29, 2021
  • Image attribution tooltip
    libre de droit via Getty Images

    Bluebird, after delays, gets speedy FDA review for beta thalassemia gene therapy

    The regulator will decide whether to approve Bluebird's treatment by next May, but its evaluation is beginning more than a year later than the biotech hoped.

    By Nov. 22, 2021
  • Trendline

    Gene Therapy

    Rapid scientific advances have put the gene therapy field at the forefront of biomedical research. But, as recent setbacks have shown, researchers and drugmakers still face major challenges. 

    By BioPharma Dive staff
  • Image attribution tooltip
    Permission granted by Ed Shipman for Mass Eye and Ear
    Deep Dive

    Years later, a first-of-its-kind treatment shows the power, and limits, of gene therapy

    Luxturna, approved four years ago as the first gene therapy for an inherited disease in the U.S., is improving sight and quality of life for several of the patients who received it.

    By Nov. 15, 2021
  • Image attribution tooltip
    Courtesy of Sanofi

    Eye-focused gene therapy startup gets $60M cash infusion from Sanofi

    Shortly after postponing a $135 million IPO, Gyroscope has found another way to back a treatment for a disease that's become a top target of multiple drugmakers.  

    By Nov. 8, 2021
  • Image attribution tooltip
    Artur Plawgo via Getty Images

    Beam gets green light to begin first clinical test of base editing

    Alongside the milestone, the gene editing biotech also announced John Maraganore, who will soon step down as Alnylam's CEO, will join its board.

    By Nov. 8, 2021
  • Image attribution tooltip
    Kena Betancur via Getty Images

    Blackstone continues biotech push with up to $250M cell therapy investment

    The investment in CAR-T maker Autolus Therapeutics adds to a string of biotech deals the private equity firm has made since 2018.

    By Nov. 8, 2021
  • Image attribution tooltip
    Jeenah Moon via Getty Images

    Pfizer gene therapy research delayed by trial changes, safety questions

    Data readouts for Pfizer's hemophilia gene therapies are now expected later than previously forecast, while the company also works through modifying a trial of its Duchenne treatment.

    By Nov. 3, 2021
  • Image attribution tooltip
    Mario Tama via Getty Images

    FDA extends review of J&J, Legend's cell therapy for multiple myeloma

    The three-month delay could give an advantage to Bristol Myers Squibb, which holds the first approval for a CAR-T therapy for the blood cancer.

    By , Nov. 2, 2021
  • Image attribution tooltip
    Maddie Meyer via Getty Images

    Moderna, teaming with a startup, wades further into gene editing

    The biotech has identified gene editing as a natural fit for the technology it uses to deliver its vaccines and drugs. A deal with Metagenomi, a startup backed by Bayer, will further those ambitions.

    By Nov. 2, 2021
  • Image attribution tooltip
    Lydia Polimeni, National Institutes of Health

    NIH, FDA spearhead broad partnership to speed gene therapy research

    The two institutions will work with drugmakers and nonprofit groups on a wide-ranging initiative meant to make the complex treatments easier and less costly to produce. 

    By Kristin Jensen • Oct. 28, 2021
  • Image attribution tooltip
    Mario Tama via Getty Images

    Vertex aligns with another CRISPR gene editing startup

    A new alliance with Mammoth Biosciences marks the latest evidence of Vertex's interest in gene editing, which has already been the focus of multiple deals with emerging biotechs. 

    By Oct. 26, 2021
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Bluebird, winding down in Europe, withdraws another rare disease gene therapy

    The biotech won EU approval for two gene therapies, Zynteglo and Syksona, both of which it will pull from market after difficulties negotiating reimbursement.

    By Oct. 21, 2021
  • Boehringer Ingelheim takes next step in development of cystic fibrosis gene therapy

    Drugs from Vertex can effectively treat the lung disease in as much as 90% of patients. Gene therapy could be a solution for the remaining 10%, but the path forward is challenging.

    By Oct. 19, 2021
  • Image attribution tooltip
    Getty Images

    Takeda takes aim at a biotech's gene therapy work

    For an upfront payment of $45 million, Takeda gains access to as many as eight programs from Poseida Therapeutics and a potential method of delivering gene therapies without the help of viruses.

    By Oct. 12, 2021
  • Image attribution tooltip
    Permission granted by Intergalactic Therapeutics

    Intergalactic Therapeutics launches with $75M to build a new type of gene therapy

    Founded by former Biogen executive Michael Ehlers and backed by Apple Tree Partners, Intergalactic aims to create non-viral gene therapies delivered via an advanced form of electroporation.

    By Oct. 7, 2021
  • Image attribution tooltip
    Jeenah Moon via Getty Images

    Gene therapy developer gets chance at a comeback with Pfizer deal

    Voyager Therapeutics recently scrapped much of its pipeline and replaced top executives. Now, a Pfizer deal on new technology gives investors hope.

    By Oct. 6, 2021
  • Image attribution tooltip
    Courtesy of Sarepta

    Sarepta embarks on late-stage clinical trial of Duchenne gene therapy

    Initiation of the Phase 3 trial is an important milestone for the biotech after earlier setbacks, as well as for patients with the inherited muscle disease.

    By Oct. 4, 2021
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Amicus, looking for a boost, sells its gene therapy work to a SPAC

    The value of the biotech's growing gene therapy portfolio has been "unrecognized" by investors, said CEO John Crowley, leading to a sudden shift for an initiative that began just three years ago.

    By Sept. 29, 2021
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Worrisome side effects lead Pfizer to narrow Duchenne gene therapy trial

    Outside trial monitors have attributed three cases of severe muscle weakness to Pfizer's treatment, causing the company to change the design of its closely watched Phase 3 study.

    By Sept. 28, 2021
  • Image attribution tooltip
    Sarah Silbiger via Getty Images

    FDA lifts hold on GeneTx, Ultragenyx study of Angelman therapy

    The hold, which was put in place during the fourth quarter last year, came after five patients in an early trial experienced muscle weakness following treatment.

    By Sept. 27, 2021
  • Image attribution tooltip

    Novartis pushes further into gene therapy for the eye with deal for Swiss startup

    The large drugmaker has acquired Arctos Medical and its preclinical research into optogenetics, an area Novartis already showed interest in with its buyout of Vedere Bio last year.

    By Updated Sept. 23, 2021
  • Image attribution tooltip
    Getty / Edited by BioPharma Dive

    Fourth trial volunteer dies in Astellas gene therapy study

    The study, which was suspended following three deaths last year, had been restarted in February after Astellas lowered the treatment dose used. 

    By Sept. 14, 2021
  • Image attribution tooltip

    AbbVie bets big on a gene therapy for eye diseases

    The company has agreed to pay $370 million, and possibly north of $1 billion more, to gain access to a Regenxbio treatment targeting wet AMD and other eye conditions.

    By Sept. 13, 2021
  • Image attribution tooltip
    metamorworks via Getty Images
    Sponsored by Yourway

    Cell and gene therapies' evolving temperature-controlled requirements call for specialized logistics solutions

    The CGT industry is expected to grow 30% between 2019 and 2025, and the transition from clinical trials to commercial-scale production is now seen as inevitable.

    By Leandro Moreira, Yourway • Sept. 13, 2021
  • Lilly joins RNA editing race with ProQR deal

    An agreement with the Dutch biotech, which could be worth as much as $1.3 billion, expands Lilly's work in genetic medicine research.

    By Kristin Jensen • Sept. 9, 2021